Navigation Links
Genmab Announces Year End 2007 Financial Results
Date:3/31/2008

three milestones in Roche collaboration

Gained rights to HuMax-CD4 and HuMax-TAC from Merck Serono and HuMax-IL8

through asset exchange with Medarex

Commenced seven new studies:

HuMax-EGFr - Phase III front line head and neck cancer study by DAHANCA

and Phase II non small cell lung cancer study

HuMax-CD20 - Phase II front line CHOP combination study in follicular

non-Hodgkin's lymphoma, 2 RA Phase III studies, Phase II relapsed

diffuse large B-cell lymphoma study

HuMax-CD38 Phase I/II multiple myeloma study

Achieved positive clinical trial results:

HuMax-CD20 Phase II RA data

Final HuMax-CD4 Phase II cutaneous T-cell lymphoma (CTCL) data

R1507 Phase I sarcoma data

Presented pre-clinical data:

Positive data for HuMax-HepC, HuMax-EGFr and HuMax-CD20

Unique mechanisms of action of HuMax-CD4 and HuMax-EGFr

Financial Highlights:

Cash position increased for fourth consecutive year

Achieved membership in OMXC20 index on the OMX Nordic Exchange

Copenhagen

2008 Guidance

We expect to significantly expand development in 2008 in our clinical and pre-clinical programs, including plans to initiate 17 new clinical studies, filing our first biologics license application and selecting two new clinical candidates. We will pay development costs for the new and ongoing pivotal studies in HuMax-CD4 and HuMax-EGFr. Under our collaboration with GSK, we will fund half the development costs for the trials with HuMax-CD20. We expect to continue our increasing level of discovery and pre-clinical work in 2008, developing antibody products for a variety of new and existing disease targets. Finally, the 2008 projections include operating costs from the newly acquired antibody manufacturing facility.

Due to these expanded activities, Genmab's operating costs are expected to be higher in 2008 than in 2007. In combination with increasing re
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Pipette.com has added the ... comprehensive portfolio of Eppendorf products. , The Eppendorf Centrifuge ... Centrifuge 5424/5424 R and receive the following:, ... plus or Eppendorf Reference 2 ,     3 ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project ... the legal requirements around using controlled substances in pharmaceutical ... As their international operations expand and become increasingly complex, ... as a result of the first phase of the ...
(Date:1/22/2015)... 22 de enero de 2015  El Dr. Paul ... llamada a nominaciones para 2015. Este prestigioso premio reconoce ... tiene el potencial para hacer, contribuciones destacadas para la ... hasta el 15 de marzo de 2015 a través ...
(Date:1/22/2015)... CAMBRIDGE, Mass. , Jan. 22, 2015   GenoSpace , ... suite of tools to enable the broad use of genomic, ... today announced the appointment of Michelle Munson , CEO ... independent director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Global Compliance Service for Controlled Substances to Expand to China 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4GenoSpace Expands Board with Appointment of Michelle Munson 2
... Groton , Connecticut MORRISVILLE, N.C., May ... of APIs, intermediates and Drug Products to the pharmaceutical industry, ... announce the recent award by Pfizer Inc. as the 2008 ... Groton, Connecticut R&D center on May 1, 2009. The award ...
... Blinatumomab in NHL and ALL Highlighted at the ... Combination Data in Breast Cancer to Be Presented ... MeetingBETHESDA, Md., May 20 Micromet, Inc. (Nasdaq: ... novel, proprietary antibodies for the treatment of cancer, ...
... WOODMERE, N.Y., May 19 In an eleventh-hour attempt ... QGLY ) has issued a press release claiming that ... a key staff member of a subsidiary of Quigley, and ... who have offered their own slate of Quigley,s Board of ...
Cached Biology Technology:Pfizer Global R&D Presents 2008 Top Intermediates CMO Award to Asymchem 2Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 2Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 3Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 4Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 5In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharma Division 2In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharma Division 3
(Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
(Date:1/22/2015)... 16, 2015  A man-made form of insulin delivered by ... capabilities in adults with mild cognitive impairment and Alzheimer,s ... researchers at Wake Forest Baptist Medical Center. ... mild cognitive impairment (MCI) or mild to moderate Alzheimer,s ...
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small ... Brands report showed that planet-wide, transactions at merchants on the ... the total number of credit, debit, and prepaid cards reached ... were victims of fraudulent card usage in 2012, and credit ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... Epitomics, Inc. announced today that it has signed a ... HealthCare). Epitomics will use its proprietary rabbit monoclonal antibody ... identification and validation. "Epitomics has had ... is a major expansion of our collaboration and confirms ...
... German . Medicines from plants ... that has nothing in common with what the researchers ... Ecology IME in Aachen, Germany, are doing. They use ... many other medications, cannot be chemically produced. Biologically ...
... persist in the often violently competitive realm of bacteria, ... University Bloomington biologists have learned that in one bacterium, ... cheaters and arrest their bids for dominance. ... suppress social cheaters," said Gregory Velicer, who with Ph.D. ...
Cached Biology News:Medicines from plants 2'Policing' stops cheaters from dominating groups of cooperative bacteria 2'Policing' stops cheaters from dominating groups of cooperative bacteria 3'Policing' stops cheaters from dominating groups of cooperative bacteria 4
... Designed to histochemically ... in distinct pH in ... sections. The specific marker ... senescent cells (not found ...
Human/Mouse/Rat JNK Pan Specific Affinity Purified PAb...
Request Info...
Cyan Standard is 7-hydroxy-4-trifluoromethylcoumarin...
Biology Products: